What Is P21 (P021)?

1. What kind of peptide is P21?

P021 starts with four amino acids from CNTF: aspartic acid, glycine, glycine and leucine, abbreviated DGGL. Researchers added an adamantane-containing terminal building block, described in the papers as adamantylated glycine. The 2017 methods section describes the resulting compound as a pentapeptide with a molecular weight of 578.3.

This explains why descriptions alternate between “tetrapeptide” and “pentapeptide.” Four residues form the CNTF-derived core; the modified compound includes the extra terminal unit. The sequence is written Ac-DGGLᴬG-NH₂. Plain-text versions can lose the superscript, obscuring the modified residue.

The original Li et al. paper calls the compound P21. Later research generally uses P021. Searching the latter helps avoid papers about CDKN1A/p21, a protein that helps regulate cell division. Findings about that protein in cancer or cellular senescence do not establish benefits or risks for this nootropic peptide.

2. How might P21 affect BDNF and memory?

BDNF stands for brain-derived neurotrophic factor. It helps support neurons and synaptic plasticity, the ability of connections between neurons to change. Neurogenesis means the formation of new neurons. These processes overlap, but increasing a synaptic protein and producing a new, functional neuron are different outcomes.

P021 researchers propose that the compound inhibits leukemia inhibitory factor (LIF) signaling and increases BDNF expression. In Kazim and colleagues’ 2014 experiments, the proposed downstream effect involved reduced activity of GSK3β, an enzyme implicated in abnormal modification of tau. Tau is a protein that becomes part of the tangles associated with Alzheimer’s disease.

That gives researchers a mechanism to test. It does not supply an expected gain in vocabulary recall, concentration or IQ. A higher BDNF measurement in brain tissue cannot be converted into a percentage improvement in memory.

The location and experimental setting matter too. A compound can affect cultured cells while failing to produce the same response in a living brain. The 2024 study below tested that gap directly.

3. What do the P21 studies show?

The evidence spans several questions: enhancement in normal mice, cognitive aging, Alzheimer’s-like disease and a genetic developmental disorder. They should not be pooled as if they measured the same benefit.

The 2010 normal-mouse study is relevant to enhancement claims because the animals did not need an Alzheimer’s-like disease model to respond. Still, a mouse remembering an object or platform location cannot tell us whether a person learns a language faster. That requires testing people with outcomes such as delayed recall and retained learning.

In the 2017 study, behavioral groups began with 14 treated disease-model mice, 15 untreated disease-model mice and 20 healthy controls. Water-maze testing followed nine months of treatment. These timelines give little support to claims of an immediate focus effect or a short “brain repair” cycle.

The 2024 investigators also tried daily intraperitoneal injections for 30 days in adult mice. Changing exposure did not recover the expected BDNF response. A different disease model cannot overturn every earlier finding, but it narrows claims that P021 reliably raises BDNF wherever it is used.

Several positive papers share investigators. The 2024 paper also includes a P021 patent holder and discloses his role at Phanes Biotech. Multiple publications therefore provide less independent replication than their number alone might suggest.

A 2026 paper by Falangola and colleagues examines diffusion MRI measures after early P021 treatment in the same Alzheimer’s mouse model. It has a linked corrigendum. We could verify the publication records but could not retrieve the full article and correction for this guide, so we do not use them to support efficacy claims.

4. Has P21 been tested in humans?

Targeted PubMed and Europe PMC searches for P021 and CNTF-derived peptide research identified no published human intervention study for this guide. Searches of ClinicalTrials.gov on September 22, 2026 used P021, P21 with peptide or CNTF, Ac-DGGL, and CNTF peptide mimetic. None identified a trial administering this compound.

The broad P021 registry search returned five records, all unrelated. A search hit can contain a matching protocol identifier without studying the peptide. Similarly, human cancer research involving the p21 protein should not be counted as P021 clinical evidence.

These searches cannot exclude unpublished work or development under another name. They do mean the reviewed evidence cannot answer the questions a prospective user needs answered: whether memory improves, what exposure is tolerable, how often adverse effects occur and what repeated use does.

5. P21 dosage, oral delivery and injections

No validated human nootropic dose or cycle emerged from the research reviewed here. The 2017 mouse experiment used 60 nanomoles per gram of food. That is a feeding concentration, not a body-weight dose and not a human dosing instruction.

Converting an animal amount by body weight leaves several unknowns untouched: absorption, metabolism, brain exposure and sensitivity to the compound. A calculation cannot replace dose-ranging and safety studies.

Oral animal findings do make P021 interesting as a drug-development candidate. They do not establish the bioavailability of a capsule sold online. Formulation, identity and the amount of intact compound absorbed would all need verification.

The reviewed studies also provide no human comparison of oral, intranasal and subcutaneous P021. An injection into a mouse’s abdominal cavity does not validate a subcutaneous protocol in people. Research on Semax nasal delivery concerns a different molecule and cannot supply the missing P021 measurements.

6. P21 half-life and the three-hour claim

The 2017 paper reports plasma stability exceeding three hours and stability in artificial digestive fluids. Those observations concern resistance to degradation under the stated conditions. They do not establish a human elimination half-life.

An elimination half-life requires concentration measurements over time in the body. Absorption, distribution and clearance all affect that curve. A molecule may resist enzymes in a sample while leaving the circulation through other processes.

The duration of a cognitive effect is a third question. Even if a compound initiates a biological response, the response could follow a different timeline from its blood concentration. Neither laboratory stability nor a subjective sense of focus establishes how long intact P021 remains in the brain.

A peptide half-life model will draw a curve from whatever value is entered. For P021, that curve would represent an assumption, with no validated basis for choosing a redosing interval.

7. P21 side effects and safety

The human evidence reviewed here cannot establish a dependable side-effect profile. Describing headache, insomnia or anxiety as “common P21 side effects” would require systematically collected observations and a known number of exposed people. Online anecdotes do not provide that denominator.

The same problem applies to “no side effects.” A report of uneventful use cannot rule out uncommon reactions or delayed harm. Effects on mood, sleep, tolerance, reproduction and long-term neurological health remain unresolved in people.

Product testing answers narrower questions. Analytical identification can help determine whether a sample matches P021; content testing can estimate how much it contains. A purity percentage alone cannot establish identity, sterility or clinical safety. A batch report should specify the substance, method and tested batch.

Interest in neuronal growth also raises cancer questions. The reviewed studies do not establish whether P021 changes human cancer risk in either direction. Papers about the unrelated CDKN1A/p21 protein cannot settle that question.

8. P21 vs Semax, Adamax and Cerebrolysin

These compounds appear together in nootropic discussions, but their chemistry and research histories differ. The linked guides examine each evidence base in detail.

P021’s development from CNTF does not make it a purified version of Cerebrolysin. Nor does adding an adamantane-related group make Adamax interchangeable with P021: the peptide backbones differ.

No controlled human evidence identified here establishes a benefit from stacking P021 with these compounds or Selank. Shared references to BDNF do not demonstrate additive effects or interaction safety.

For readers following the next round of research, a useful human study would measure retained learning and attention accuracy alongside sleep, mood and adverse events. It would identify the exact formulation, compare it with placebo and follow participants through repeated exposure. Those results would help readers weigh measurable benefits against risks; the current animal literature cannot supply them.

9. P21 FAQ

• What is P21 peptide used for?

  P21, also called P021, is an experimental peptide investigated for learning, memory, neurogenesis and synaptic function. Its published evidence concerns cells and animals; the searches for this guide identified no clinical trial establishing a human benefit.

• Are P21 and P021 the same?

  The original 2010 peptide paper used P21; later papers commonly use P021. Both names refer to the CNTF-derived compound discussed here. The unrelated p21 protein encoded by CDKN1A regulates the cell cycle.

• Does P21 increase BDNF?

  Some rodent experiments reported increased brain-derived neurotrophic factor. A 2024 CDKL5-deficiency mouse study did not reproduce that increase. There is no established percentage increase for a healthy human brain.

• Can P21 grow new neurons or improve memory?

  Animal experiments reported changes in neurogenesis markers and memory tasks. These support further research, but cannot predict how many new functional neurons a person would develop or how much their memory would improve.

• What is the recommended P21 dosage?

  No validated human dose or cycle was identified. Animal feeding concentrations and injection experiments cannot establish a safe nootropic regimen, even after adjusting for body weight.

• What is P21's half-life?

  A dependable human elimination half-life has not been established. The often-cited greater-than-three-hour figure concerns preclinical plasma stability; it cannot determine human clearance or a redosing interval.

• Does oral P21 work better than nasal spray or injections?

  Several animal studies used oral P021. No human comparison establishes oral, intranasal or subcutaneous effectiveness, absorption or safety. Oral activity in mice does not validate a retail capsule or spray.

• What are P21's side effects?

  The available evidence does not provide reliable human side-effect frequencies. Effects on sleep, mood, interactions and long-term exposure remain unresolved. Animal tolerability observations cannot establish safety in people.

• Is P21 better than Semax or Adamax?

  No human head-to-head trial was identified. The compounds have different structures and evidence bases, so shared BDNF claims or chemical modifications cannot establish a potency ranking.

10. Sources